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Abstract 
T-cell acute lymphoblastic leukemia (T-ALL) is a malignant disease of the bone 
marrow in which early lymphoid T-precursor cells proliferate and replace normal 
hematopoietic cells. Despite there has been remarkable progress in the development of 
effective treatments against T-ALL, 20% of the patients still exhibit poor response to the 
current chemotherapeutic regimens and the cause of treatment failure in these patients is 
still largely unknown. Defects in the apoptotic pathway may account for chemoresistance 
in at least some T-ALL patients since chemotherapy acts primarily by inducing apoptosis. 
Therefore, better understanding of the mechanisms that cause resistance to apoptosis in 
T-ALL cells may provide insights into the development of novel strategies for the 
treatment of T-ALL patients with unfavorable response to anticancer drugs. 
By studying the cellular responses to an apoptogenic drug, etoposide, we identified 
an apoptosis-resistant T-ALL cell line, Sup-Tl. We showed that Sup-Tl cells were 
deficient in etoposide-induced activation of caspases and mitochondrial cytochrome c 
release. However, addition of exogenous cytochrome c in cell-free apoptosis reactions 
induced prominent caspase-3 activation, indicating that the chemoresistance observed in 
Sup-Tl cells is due to its insusceptibility to the drug-induced mitochondrial alterations. 
Analysis of expression of the Bcl-2 family proteins revealed that the levels of Bax, Bcl-2 
and Bim in Sup-Tl cells were differed from etoposide-sensitive T-ALL cell lines. 
i 
Transient transfection of BiniEL into Sup-Tl cells significantly restored their sensitivity to 
the etoposide-induced apoptosis. This provides direct evidence showing that the 
expression level of Bim is an important determinant for the sensitivity of T-ALL Sup-Tl 
cells to the etoposide-induced apoptosis. 
Further experiments revealed that the lack of BiniEL expression in Sup-Tl cells was 
due to the rapid degradation of newly-synthesized BiniEL by the proteosomal pathway, as 
treatment of Sup-Tl cells with a proteosome inhibitor significantly restored the protein 
level of BiniEL. In addition, we showed that constitutive activation of the JNK pathway in 
Sup-Tl cells was responsible for promoting BiniEL phosphorylation, and this serves as a 
signal targeting BiniEL to the proteosome for degradation. Altogether, our findings 
represent a possible mechanism of chemoresistance in T-ALL cells, and provide new 
insights into the regulation of Bim and the role of JNK pathway in cell survival. It is 
expected that these findings will help to develop novel, target-based strategies for the 
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. Chapter 1 
Chapter 1 General Introduction 
1.1 Acute lymphoblastic leukemia 
Acute lymphoblastic leukemia (ALL) is a rapidly progressing disease results from 
the neoplastic proliferation of immature lymphoid cells called lymphoblasts. Normally, 
blasts constitute 5% or less of the healthy bone marrow. In ALL, however, these blasts 
remain abnormally immature and multiply continuously, eventually constituting between 
30% to 100% of the bone marrow. The expanded lymphoblast population fills up the 
bone marrow and prevents the production of healthy red cells, platelets, and mature 
leukocytes. Consequently, anemia, thrombocytopenia, and neutropenia develop, which, if 
untreated, become lethal. ALL is the most common type of malignancy in children and 
constitutes 80% of the leukemia up to the age of 15. In adults, ALL is relatively less 
common and constitutes 15-20% of all cases of acute leukemia (Berg et al., 2000). 
Immunophenotyping of ALL blast cells is the major method for classifying ALL subtypes. 
By detection of lineage-specific antigens, ALL blast cells can be subdivided into 
B-lineage and T-lineage acute lymphoblastic leukemia. ALL blast cells that express the 
B-lineage markers can also be subclassified into mature B-cell acute lymphoblastic 
leukemia (B-ALL) and precursor B-cell acute lymphoblastic leukemia (pre-B-ALL). 
Whereas, those express T-lineage markers are generally termed as T-cell acute 
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lymphoblastic leukemia (T-ALL) (Foon et al., 1980). Approximately 15% of children and 
adults with ALL are diagnosed as T-ALL, and the rest are of the B-lineage (Pui, 2005). 
1.2 T-cell acute lymphoblastic leukemia 
1.2.1 Chemotherapy 
Chemotherapy is the primary treatment for T-ALL. It is generally divided into three 
phases: induction, intensification, and maintenance. Many patients also receive treatment 
called intrathecal chemotherapy to prevent leukemia from spreading to the central 
nervous system. 
1.2.1.1 Induction therapy 
Induction therapy of T-ALL aims to induce complete remission. To achieve complete 
remission, the leukemic burden has to be reduced by 99%. Typically, 4 to 5 drugs are used 
for remission induction. The current regimens contain vincristine, steroids, and 
daunorubicin plus either asparaginase or cyclophosphamide. Similar outcomes were 
evidenced from different induction therapy programs, with approximately 80-90% of the 
patients achieve a complete remission (Larson, 2003). 
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1.2.1.2 Intensification therapy 
Intensification therapy is designed to eradicate the rapidly proliferating blast cells 
that are responsible for early relapse. Drugs given for this purpose are usually 
antimetabolites such as methotrexate. The need for intensive intensification therapy to 
achieve a cure, unlike that of remission induction therapy, is controversial. In randomized 
trials, increasing doses of chemotherapy during intensification therapy did not improve 
the results (Ribeiro and Pui, 2005). 
1.2.1.3 Maintenance therapy 
For maintenance therapy, T-ALL patients receive a prolonged period of treatment 
with low doses of chemotherapeutic drugs. The period of maintenance therapy is 
depended on the intensity and success of the previous phases of chemotherapy. Typically, 
1 to 3 years of 6-mercaptopurine and methotrexate are often used in this phase of therapy 
(Larson, 2003). 
1.2.2 Chemoresistance in T-ALL 
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Previous studies have shown that patients with T-ALL have poorer treatment success 
than those with B-lineage ALL. Henze et al reported that the 9-year probability of 
continuous complete remission were 9% 士 9o/o and 41o/o 士 5o/o�for patients with T-lineage 
ALL and non-T-lineage ALL, respectively (Henze et al, 1981). Although treatment 
outcome in newly diagnosed T-ALL has improved significantly in several recent clinical 
trials (Goldberg et al.’ 2003; Pui et al, 2004), higher rates of induction failure, induction 
death and early relapse are consistently found in T-ALL patients. These clinical data 
suggest that patients with T-ALL may be more resistant to conventional 
chemotherapeutic agents. 
Owing to the remarkable progress in the treatment strategies, T-ALL is now curable 
with chemotherapy in over 80% of patients. However, the cause of treatment failure in the 
remaining patients is still largely unknown. Only a few reports have highlighted the 
underlying mechanisms. The cause of glucocorticoids resistance is controversial. Quddus 
et al. reported that glucocorticoids receptor levels in leukemic cell could not be used to 
predict the treatment outcome (Quddus et al., 1985). However, Costlow et al. reported 
that lower glucocorticoids receptor levels were correlated with unfavorable presenting 
features (Costlow et al” 1982). More recently, several differentially expressed genes have 
been identified in ALL cells with resistance to prednisone, vincristine and daunorubicin, 
whose pattern of expression is related to treatment outcome (Holleman et al., 2004). 
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However, it is still not known whether modulation of the proteins encoded by these genes 
will enhance treatment efficacy in patients with drug-resistant ALL. 
1.3 Apoptosis and chemoresistance 
Cells have an inherent suicidal program called apoptosis. Since chemotherapeutic 
drugs act primarily by inducing apoptosis, defects in the apoptotic machinery can make 
cancer cells resistant to therapy. Thus, understanding of how tumor cells resist apoptosis 
might lead to the development of novel therapeutics that target at restoring apoptosis 
sensitivity (Igney and Krammer�2002). 
1.3.1 Initiation，execution and regulation of apoptosis 
1.3.1.1 Initiation of apoptosis 
Apoptosis can be initiated by two distinct pathways. The extrinsic pathway is 
mediated by death receptors on the cell surface. The intrinsic pathway is mediated by 
mitochondria (Krammer, 1999). Both pathways ultimately converge on the activation of 
cysteine aspartyl-speciflc proteases (caspases). Activated caspases in turn cleave cellular 
death substrates, resulting in the biochemical and morphological changes that are 
hallmarks of apoptosis. 
5 
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The extrinsic pathway is activated by the engagement of death receptors on the cell 
surface. Binding of death ligand such as FasL or tumor necrosis factor (TNF) to their 
respective receptors recruits Fas-associated death domain (FADD) and pro-caspase-8 to 
form a complex known as death-induced signalling complex (DISC). Oligomerization of 
pro-caspase-8 in the DISC autoactivates and releases mature caspase-8, which functions 
as an initiator caspase (Salvesen and Dixit, 1999). Depending on the cell type, active 
caspase-8 induces apoptosis by two different signalling pathways. In type I cells, large 
amount of active caspase-8 formed at the DISC induces apoptosis directly. In type II cells, 
the small amount of active caspase-8 is insufficient to initiate apoptosis directly. To 
overcome the problem, caspase-8 cleaves the BH3-only protein Bid to generate an active 
fragment, tBid, which activates the intrinsic pathway (Scaffidi et al., 1998). 
The intrinsic pathway, on the other hand, is initiated by permeabilization of the 
mitochondrial membrane. Loss of the mitochondrial membrane potential induces leakage 
of apoptogenic molecules including cytochrome c, SMAC/DIABLO and apoptosis 
inducing factor into the cytosol (Zamzami and Kroemer, 2001). In the cytosol, 
cytochrome c induces the oligomerization of Apaf-1 (apoptotic protease activating 
factor-1) in the presence of dATP (deoxyadenosine triphosphate). Apaf-1 oligomers in 
turn recruit pro-caspase-9 to form a complex known as apoptosome. Within the 
apoptosome, cleavage of pro-caspase-9 yields active caspase-9 which functions as an 
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initiator caspase. 
1.3.1.2 Execution of apoptosis 
Activated initiator caspases process and activate the downstream effector caspases 
including caspase-3, -6 and -7. Active effector caspases, in turn, cleave cellular death 
substrates, resulting in the biochemical and morphological alterations of apoptosis 
(Earnshaw et al., 1999). Caspase substrates in cytoskeleton include actin, p-catenin, and 
gelsolin. Cleavage of these proteins leads to the formation of apoptotic bodies. 
Cleavage of nuclear lamins such as lamin A will result in nuclear shrinkage. DNA 
fragmentation is associated with the cleavage of ICAD (inhibitor of the caspase-activated 
deoxyribonuclease). Moreover, effector caspases also cleave proteins involved in DNA 
repair, signal transduction pathways, and cell cycle regulation (Earnshaw et al., 1999). 
1.3.1.3 Regulation of apoptosis 
Apoptosis is stringently controlled and can be regulated by different classes of 
molecules at various levels. Apoptosis can be regulated at the mitochondrial level by 
members of the Bcl-2 family proteins. The human Bcl-2 family comprises over 20 
molecules that can be classified functionally into anti-apoptotic and pro-apoptotic 
members (Cory and Adams, 2002). These proteins contain 1 to 4 conserved Bcl-2 
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homology (BH) domains. Examples of the anti-apoptotic members are Bcl-2, BC1-XL, 
Bcl-w�and Mcl-l. They are localized to the mitochondrial outer membrane where they 
prevent the release of mitochondrial cytochrome c into the cytosol. The pro-apoptotic 
members can be subdivided into 2 subfamilies. The Bax subfamily comprises Bax, Bak� 
and Bok. They share sequence homology among the BHl, BH2 and BH3 domains. The 
BH3-only subfamily comprises Bad, Bid, Noxa�Puma, Bik, Bim, Bmf, and Nip-3. 
BH3-only proteins act as sensors of cellular damage and initiate the death process. Upon 
apoptotic stimuli, these proteins undergo post-translational modifications and redistribute 
to mitochondria. For example, Bid is cleaved and activated by caspase-8 and Bim is 
detached from dynein motor complex (Puthalakath and Strasser, 2002). BH3-only 
proteins, in turn, induce mitochondrial permeabilization either by inhibiting the 
anti-apoptotic proteins or by activating pro-apoptotic proteins of the Bax subfamily 
(Bouillet and Strasser, 2002). 
Apoptosis can also be regulated at the level of caspase activation by two classes of 
proteins. The inhibitor of apoptosis (lAP) proteins is originally identified because of their 
ability to inhibit apoptosis in the baculovirus-infected cells. Nine lAP family members 
including XIAP, c-IAPl, C-IAP2, NAIP�MLIAP, ILP2, livin, apollon and survivin have 
been identified in human cells. All of these proteins possess at least one domain known as 
baculoviral lAP repeat, which is essential for their anti-apoptotic function. Unlike the 
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Bcl-2 family of proteins, lAPs directly bind to and inhibit caspase-3，-7，and -9 (Salvesen 
and Duckett, 2002). 
FLIPs (FADD-like interleukin-1 p-converting enzyme-like protease-inhibitory 
proteins) represent another class of proteins that can regulate apoptosis at the level of 
caspase activation. However, unlike lAPs, they inhibit apoptosis at the level of death 
receptors (Krueger et al.，2001). FLIPs contain an inactive caspase-8-like catalytic 
domain at the C-terminus and they are recruited to the DISC during apoptosis, thus 
preventing procaspase-8 recruitment and activation. 
1.3.2 Mechanisms of resistance to apoptosis 
1.3.2.1 Overexpression of pro-survival proteins 
Numerous studies have shown that overexpression of anti-apoptotic proteins can 
render tumor cells resistant to apoptosis. Bcl-2 overexpression was initially described in 
follicular lymphomas as a result of a t(14;18) translocation to the immunoglobulin locus 
(Tsujimoto et al., 1985). Enhanced expression of Bcl-2 prevents apoptosis induced by 
chemotherapeutic drugs, including alkylating agents and topoisomerase inhibitors 
(Kamesaki et al., 1993; Walton et al, 1993). Moreover, studies in clinical samples have 
revealed a correlation between high expression of Bcl-2 and poor prognosis in a number 
of tumors, including acute myelogenous leukemia, acute lymphocytic leukemia, 
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non-Hodgkin's lymphomas, and prostate cancer (Reed, 1999). 
Other anti-apoptotic Bcl-2 family members may also involve in determining 
sensitivity of tumor cells to apoptosis. For example, high BC1-XL levels are correlated with 
poorer prognosis in patients with lymphomas (Bairey et al., 1999), squamous cell 
carcinoma (Aebersold et al, 2001), soft-tissue sarcomas (Kohler et al., 2002), and 
myelodysplastic syndrome (Boudard et al., 2002). Moreover, overexpression of Mcl-l 
was found to cause a prolongation of cell viability under various conditions that cause 
apoptotic cell death (Zhou et cd.，1997). 
High levels of FLIP are evidenced in melanomas (Irmler et al., 1997) and gastric 
adenocarcinoma (Zhou et al” 2004). Expression of these proteins blocks apoptosis 
induction at the level of the death receptors. Thus, FLIP expression cannot inhibit cell 
death induced by granzyme, chemotherapeutic drugs or 7-irradiation (Kataoka et al, 
1998). 
Recent evidence has suggested proteins of the lAP family are key determinant in 
chemoresistance in cancer cells. Downregulation of XIAP expression was shown to 
induce apoptosis and enhance chemotherapeutic sensitivity in human gastric cancer (Tong 
et al., 2005). C-IAP2 overexpression is a frequent event in pancreatic cancer and could 
therefore potentially mediate resistance in neoplastic pancreatic cancer cells (Esposito et 
al, 2006). In neuroblastoma, the expression of survivin correlates with a more aggressive 
10 
. Chapter 1 
and unfavourable disease (Adida et al, 1998). 
Cellular response to various chemotherapeutic drugs can also be determined by the 
Akt survival pathway. Transfection of constitutively active Akt in lung cancer cells 
hampers topotecan-induced apoptosis (Nakashio et al, 2000). Fibroblasts overexpressing 
Akt are resistant to the staurosporine-induced apoptosis (Tang et al., 2001). PTEN, the 
antagonist of Akt pathway, is frequently deleted in tumors, and a significant rate of PTEN 
mutations can be found in various cancer types (Steck et al” 1997; Suzuki et al., 1998). 
PTEN-deficient tumor cell lines and tumors derived from PTEN-knockout mice are 
resistant to apoptotic stimuli (Wu et al., 2003). 
1.3.2.2 Downregulation and mutation of pro-apoptotic proteins 
Besides overexpression of anti-apoptotic genes, tumors can acquire apoptosis 
/ resistance by downregulating or mutating pro-apoptotic molecules. In colon cancer and 
, hematopoietic malignancies, the pro-apoptotic Bcl-2 family member Bax is mutated 
(Rampino et al.’ 1997; Meijerink et al., 1998). Loss of expression by frameshift mutations 
and loss of function by mutations in the BH domains are the most common forms of 
mutations in these tumors. Tumor cell lines with frameshift mutations are more resistant 
to apoptosis. Reduced Bax expression is associated with a poor response rate to 
chemotherapy and shorter survival (Krajewski et al, 1995). In a transgenic mice model, 
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induction of Bax expression by p53 resulted in slow tumor growth and a high percentage 
of apoptotic cells (Krajewski et al., 1995). In Bax-deficient mice, however, tumor growth 
was accelerated and apoptosis was diminished (Yin et al., 1997). 
Tumor cells have developed various strategies to prevent the induction of 
apoptosome-driven apoptosis. Apaf-1 is an adaptor molecule that binds to and promotes 
pro-caspase-9 activation in the presence of cytochrome c. The Apaf-1 gene is frequently 
hypermethylated and therefore silenced in melanoma cells (Soengas et al., 2001) and 
human leukemia (Fu et al., 2003). Apaf-1-negative melanomas fail to respond to 
chemotherapy (Soengas et al., 2001). Recently, Apaf-1 was found to be sequestered by 
the plasma membrane in human B-lymphoma cells (Sun et al., 2005), suggesting that 
improper compartmentalization of Apaf-1 can also render tumor cells resistant to 
apoptotic stimuli. The heat shock proteins (HSPs) HSP27 and HSP70 can also prevent 
pro-caspase-9 activation at the apoptosome level. HSP27 binds to cytochrome c and 
prevents cytochrome c-mediated interaction of Apaf-1 with pro-caspase-9 (Bruey et al., 
2000), whereas HSP70 binds to Apaf-1 and prevents Apaf-1 oligomerization, thereby 
preventing the activation of pro-caspase-9 (Beere et al., 2000). Thus, HSPs might be 
involved in resistance to anticancer therapy. 
In neuroblastomas, the gene for caspase-8 is frequently inactivated by gene deletion 
or methylation. Caspase-8-deficient neuroblastoma cells are resistant to apoptosis 
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induction by doxorubicin (Teitz et al., 2000). Similarly, inactivating mutations of 
caspase-8 gene are also observed in gastric carcinomas (Soung et al., 2005). 
Moreover, death receptors are downregulated or inactivated in many tumors. The 
expression of the death receptor CD95 is reduced in some tumor cells including 
hepatocellular carcinomas, neoplastic colon epithelium, and melanomas (Strand et al, 
1996). Several CD95 gene mutations have been reported in primary samples of myeloma 
(Landowski et al., 1997). Mutation, inactivation or loss of CD95, might interfere with the 
induction of apoptosis in these types of cancer. Deletions and mutations of other death 
receptors, such as TRAIL-Rl and TRAIL-R2, have also been observed in metastatic 
breast cancer (Shin et al., 2001). 
1.3.2.3 Other mechanisms 
As p53 is a well-known tumor suppressor that has a central function in apoptosis 
induction, alterations of the p53 pathway could influence the sensitivity of tumors to 
apoptosis. Studies in tissue culture have indicated that p53 deletion can render fibroblasts 
(Lowe et al, 1993) and colon cancer cells (Bunz et aL, 1999) resistant to the induction of 
apoptosis by various anticancer drugs in vitro. p53-deficient mice and transgenic mice 
that express mutant p53 showed a poor response to apoptotic stimuli (Lee and Bernstein, 
1993). Specific mutations of p53 have been linked to primary resistance to doxorubicin 
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treatment and early relapse in patients with breast cancer (Aas et al., 1996). Moreover, the 
p53-related protein, p73, mediates resistance to cisplatin in epidermoid carcinoma cells 
by blocking p53 activity (Hayashi et al., 2006). 
The transcription factor nuclear factor kappa B (NF-KB) plays an important role in 
apoptosis. In viable cells, NF-KB is retained in the cytoplasm by binding to specific 
inhibitor called inhibitor of NF-KB (IKB). Apoptotic stimuli, however, can lead to 
phosphorylation, ubiquitination, and the subsequent degradation of IKB. Free NF-KB 
translocates to the nucleus where it activates the expression of several anti-apoptotic 
genes including lAPs and BCI-XL (Karin, 2006). Cells that express constitutively activated 
NF-KB are resistant to various chemotherapeutic agents (Paillard, 1999), and enhanced 
NF-KB activity has been linked to increased expression of the anti-apoptotic genes (Karin, 
2006). Constitutive NF-KB activity confers resistance to gemcitabine in pancreatic 
carcinoma (Budihardjo et al., 1999) and to paclitaxel in prostate cancer (Flynn et al., 
2003). Conversely, NF-KB inhibition sensitizes retinoblastoma cells to doxorubicin 
(Poulaki et al., 2002). 
1.4 Bcl-2 interacting mediator of cell death 
Bim (Bcl-2 interacting mediator of cell death) is a BH3-only Bcl-2 family protein. It 
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was originally identified by screening a bacteriophage X cDNA expression library, using 
the P-labeled recombinant Bcl-2 protein as the probe (O'Connor et al., 1998). By using 
yeast-two hybrid system, Bim was independently identified as a death gene in ovarian 
tissues (Hsu et al., 1998). Bim has three major isoforms (BiniEL, BiiriL, and Bims) which 
are generated by alternative splicing. BiniEL is the largest isoform and is encoded by 
exons 2，3, 4，5 and 6 of the Bim gene. BiniL is identical to BiniEL but lacks exon 3. Bims 
is the shortest isoform that includes only exon 2, 5 and 6 (Bouillet et al” 2001). All three 
isoforms have a hydrophobic C-terminus which is essential for their insertion into the 
membrane structures in the cytosol and a BH3 domain which is essential for their 
pro-apoptotic activity (O'Connor et al., 1998). The three isoforms of Bim have different 
apoptotic potencies, with Bims being the most effective killer. This can be explained by 
the existence of additional regions in BiniEL and BiniL that attenuate their pro-apoptotic 
activity. Coimmunoprecipitation experiments demonstrated that BiniEL and BiniL, but not 
Bims, bind and sequester to LC8 of the microtubule-associated dynein motor complex, 
thereby blocking their pro-apoptotic activity under normal conditions (Puthalakath et aL, 
1999). For exertion of pro-apoptotic functions, Bim binds to and antagonizes the 
anti-apoptotic Bcl-2 family proteins including Bcl-2, BC1-XL and Mcl-l, or directly binds 
to and activates the pro-apoptotic Bax-like proteins (Marani et al, 2002). Modulating the 
activities of Bcl-2 family proteins by Bim ultimately leads to the initiation of intrinsic 
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death pathway. Bim is found in hematopoietic, epithelial, neuronal and germ cells, with 
BiniEL being the predominant isoform. In contrast, Bims is less frequently detected in 
these tissues (O'Reilly et al” 2000). 
1.4.1 Role of Bim in apoptosis 
The involvement of Bim in apoptosis was first implicated in a physiological study 
using gene-knockout mice (Bouillet et al., 1999). Bim-deficient mice have an elevated 
level of lymphoid and myeloid cells. Moreover, Bim—" lymphocytes were resistant to 
apoptotic stumuli such as cytokine deprivation, calcium ion flux, and microtubule 
perturbation. In a later study, Bim was found essential to the elimination of autoreactive 
thymocytes in the immune system (Bouillet et al., 2002), since thymocytes lacking Bim 
were found to be resistant to the apoptosis induced by T-cell receptor stimulation. Besides 
the cells in the hematological system, Bim is also required for apoptosis in neurons 
(Putcha et al., 2001) and osteoclasts (Akiyama et al., 2003). In neurons, Bim deletion 
protected neurons from the apoptosis induced by nerve growth factor withdrawal (Putcha 
et al., 2001). In osteoclasts, Bim deficiency conferred resistance to the cytokine 
withdrawal-induced apoptosis (Akiyama et al., 2003). 
Recent studies have highlighted the roles of Bim in tumorigenesis and response to a 
variety of chemotherapeutic drugs. Loss of a single allele of Bim induced the 
16 
. Chapter 1 
development of mouse B cell leukemia in Myc-transgenic mice (Egle et al., 2004). By 
screening with genome-wide array, homozygous deletion of Bim was found in the 
patients with mantle cell lymphoma (Tagawa et al., 2005). In the context of chronic 
myeloid leukemia, it was found that Bcr-Abl-positive cell line K562 expresses low levels 
of Bim (Kuribara et al., 2004). This phenomenon was recently confirmed in the primary 
leukemic cells from patients with chronic myeloid leukemia (Aichberger et al., 2005). For 
the response of tumor cells to chemotherapeutic drugs, induction of Bim is required for 
the apoptosis induced by inhibitors of histone deacetylase in Saos-2 cells (Zhao et al., 
2005). Silencing of Bim expression in these cells resulted in complete abrogation of the 
histone deacetylase inhibitor-induced apoptosis. Likewise, Bim was required for 
paclitaxel responsiveness in vitro and in tumors in vivo (Tan et al” 2005). Recently, Bim 
was found essential to the glucocorticoids-induced apoptosis in T-ALL cells (Lu et al., 
2006). Downregulation of Bim by shRNA significantly inhibited the 
glucocorticoids-induced apoptosis (Lu et al, 2006). Apparently, Bim has a very 
important role in anticancer therapy. 
1.4.2 Regulation of Bim 
The expression and pro-apoptotic activity of Bim are subjected to complex modes of 
regulation. Both transcriptional and post-transcriptional mechanisms have been 
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documented. 
1.4.2.1 Transcriptional regulation of Bim 
Several pathways have been identified in the transcriptional regulation of Bim 
expression (Puthalakath and Strasser, 2002). The mode of regulation is depended on cell 
type and the nature of stimulus. In neurons and hematopoietic cells, Bim expression was 
elevated after growth factor withdrawal (Dijkers et al., 2000; Putcha et al, 2001). The 
growth factor withdrawal-induced Bim expression requires activation of the c-Jun 
N-terminal kinase (JNK) pathway in neurons (Dijkers et al, 2000)，but requires activation 
of the Akt pathway in hematopoietic cells (Putcha et al., 2001). In fibroblasts and breast 
epithelial cells, Bim expression is depended on the inactivation of the extracellular 
signal-regulated kinase (ERK) pathway (Reginato et al., 2003; Weston et al.’ 2003). 
1.4.2.2 Post-transcriptional regulation of Bim 
In addition to the transcriptional regulation, the expression and pro-apoptotic activity 
of Bim can also be regulated by post-transcriptional mechanism. To date, the only 
identified mechanism by which Bim can be regulated post-transcriptionally is 
phosphorylation. ERK is the first kinase shown to be responsible for Bim phosphorylation. 
In vitro kinase experiments have revealed that ERK can phosphorylate recombinant 
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BiniEL, but not BiniL and Bims, at Ser-69. Moreover, transiently expressed BiniEL in 
fibroblasts can be phosphorylated by the serum-activated ERK (Luciano et al, 2003; Ley 
et al., 2004). One of the biological consequences of ERK phosphorylation is the targeting 
of BiiriEL for ubiquitination and degradation by the proteosome. Initial evidence of 
ERK-dependent degradation of BimEL was obtained from fibroblasts (Ley et al., 2003), 
and was subsequently found in lymphocytes (Mouhamad et al” 2004) and mouse 
sympathetic neurons (Lang-Rollin et al., 2004). Mutation at Ser-69 of BiniEL completely 
blocked its turnover (Ley et al, 2004), indicating that ERK phosphorylation of BiniEL at 
this residue is a critical signal for proteosomal degradation. Another biological effect of 
ERK phosphorylation of BiniEL is the prevention of its interaction with Bax. 
Phosphorylation of BiniEL at Ser-59, Ser-69 or Ser-104 significantly reduced Bax-BiniEL 
interaction, thereby preventing Bax oligomerization and apoptosis (Harada et al, 2004). 
Another kinase responsible for Bim phosphorylation is JNK. Studies in fibroblasts 
revealed that JNK could phosphorylate the recombinant BiniL in vitro at Thr-56, and 
enforced expression of activated JNK caused the appearance of phosphorylated forms of 
BiniL in vivo (Lei and Davis, 2003). JNK phosphorylation of BiniL caused its release from 
sequestration by the dynein motor complex, and is thus able to trigger apoptosis (Lei and 
Davis, 2003). JNK can also phosphorylate BimEL. In neurons, JNK was found to 
phosphorylate BiniEL at Ser-69 in response to nerve growth factor withdrawal (Putcha et 
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al., 2003). The initial evidence has shown that phosphorylation of BimEL by JNK 
potentiates apoptosis, but the detailed mechanisms still remain uncertain. 
Recently, two other kinases have been shown capable to phosphorylate Bim. In vitro 
kinase assays showed that Akt could phosphorylate recombinant BimEL, and the 
phosphorylation site was identified as Ser-87 (Qi et al, 2006). Phosphorylation by Akt in 
vivo led to the proteosomal degradation of BimEL (Qi et al., 2006). p38-mediated 
phosphorylation of BimEL at Ser-65 (equivalent to Ser-69 of human BimEL) was 
demonstrated in rat PC-12 cells (Cai et al., 2006). In contrast to Akt, p38 phosphorylation 
of BimEL was linked to the induction of apoptosis (Cai et al, 2006). 
1.5 c-Jun N-terminal kinase 
The c-Jun N-terminal kinase (JNK) is a member of the mitogen-activated protein 
kinase (MAPK) superfamily and has been demonstrated to play a critical role in apoptosis 
(Davis, 2000). JNK has three isoforms, namely JNKl, JNK2, and JNK3. JNKl and JNK2 
are widely expressed in most tissues. In contrast, the expression of JNK3 is largely 
limited to the brain, heart, and testis (Davis, 2000). The role of JNK in apoptosis is still 
under debate, as JNK has been reported to have both pro-apoptotic and anti-apoptotic 
functions, depending largely on the cell type and nature of stimulus (Lin, 2003). 
20 
. Chapter 1 
L 5. J Pro-apoptotic role of JNK 
There is numerous evidence showing that JNK functions as a pro-apoptotic kinase. 
Initial studies had been performed on neuronal cells. In rat PC-12 cells, nerve growth 
factor-induced apoptosis was efficiently blocked by expressing a dominant-interfering 
form of JNK. In contrast, activation of the JNK pathway in these cells by expressing a 
constitutively active JNK induced apoptosis (Xia et al., 1995). The pro-apoptotic role of 
JNK was further demonstrated in several gene disruption studies. Hippocampal neurons 
of mice with disrupted JNK3 gene were defective in the apoptotic response to excitotoxin 
(Yang et al., 1997). Moreover, reduced apoptosis was found in the hindbrain 
neuroepithelium of mice lacking both JNKl and JNK2 (Sabapathy et aL, 1999). JNK is 
also required for apoptosis in non-neuronal cells. Primary murine embryo fibroblasts 
lacking that lack the expression of both JNKl and JNK2 exhibited profound defect in 
apoptosis induced by UV radiation, anisomysin and methylmethanesulfonate (Toumier et 
al, 2000). 
1.5.2 Anti-apoptotic role of JNK 
In comparison, the anti-apoptotic function of JNK is not so well-characterized, but it 
has also been implicated in some earlier studies. Antisense oligonucleotides of JNK 
inhibited the growth of lung carcinoma cells (Bost et al., 1999). In addition, enhanced 
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skin papilloma development induced by 12-0-tetradecanoylphorbol-13-acetate was 
observed in JNKl null mice (She et al., 2002). Recently, the JNK-mediated cell survival 
had been demonstrated in lymphocytes, and the underlying mechanism was resolved (Yu 
et al., 2004). In an IL-3 dependent cell line, IL-3 withdrawal-induced apoptosis was 
promoted by JNK inhibition but suppressed by overexpressing a constitutively active 
JNK. Furthermore, JNK was found to exert its anti-apoptotic function by phosphorylating 
Bad, thus reducing the Bad/Bcl-XL interaction (Yu et al.’ 2004). 
1.6 Hypotheses 
Approximately 20% of the patients with T-ALL are not responsive to the current 
chemotherapeutic regimens�and these patients will eventually die of the disease. 
Unfortunately, the cause of treatment failure in these patients remains largely unknown. 
As chemotherapy acts primarily by inducing apoptosis, defects in the apoptotic pathway 
may also contribute to the chemoresistance in at least some T-ALL patients. Using 
cell-based models, we aim to investigate the molecular mechanisms that render T-ALL 
cells resistant to drug-induced apoptosis. Findings of this study would be expected to 
facilitate the development of novel treatment regimens or strategies against drug-resistant 
T-ALL. 
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Chapter 2 Materials and Methods 
2.1 Cell culture 
The human T-ALL cell lines, HSB-2, MOLT-3 and Sup-Tl, as well as the Burkitt 
lymphoma-derived cell line, Raj i�were obtained from the American Type Culture 
Collection (Rockville, MD). HSB-2 was derived from a buffy coat preparation from a 
patient with ALL (Adams et al., 1968). MOLT-3 was established from a T-ALL patient in 
relapse (Minowada et al” 1972). Sup-Tl was derived from malignant cells collected from 
pleural effusion of an 8-year-old child with T-ALL (Smith et al, 1984). Raji was 
established from a Burkitt lymphoma of the left maxilla of an 11-year-old male 
(Pulvertaft, 1964). All cell lines were grown in RPMI-1640 medium (Sigma, St. Louis, 
MO) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, Rockville, MD), 
1.5 g/L sodium bicarbonate, 1 mM sodium pyruvate, 10 mM HEPES (A^-2-hydroxy-
ethylpiperazine-7V'-2-ethanesulfonic acid), 100 U/mL penicillin and 100 |ig/mL 
streptomycin. The cells were maintained in 5% CO2 at 37 °C. Where indicated, Sup-Tl 
cells were incubated with different inhibitors including MG-132 (50 |iM), U0126 (10 |iM), 
PD98509 (10 |iM), SP600125 (10 |iM), SB203580 (15 |iM)，LY294002 (50 |iM), or 
wortmannin (100 nM), for the specified time points. All inhibitors were obtained from 
Calbiochem, La Jolla, CA. 
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2.2 Induction and quantification of apoptosis 
To induce apoptosis, the leukemic cells were seeded at an initial density of 1.5 x 10^  
cells/mL and treated with or without 1 |4,M, 5 )j-M or 10 |iM etoposide (Sigma) for the 
indicated time points. In some experiments, the cells were preincubated with 50 jiM 
z-VAD-fmk (N-benzyloxycarbonyl-Val-Ala-aspartyl-fluoromethyl ketone; Calbiochem) 
for 1 hour prior to the etoposide treatment. After treatment, the cells were washed with 
phosphate-buffered saline (PBS) and fixed in 70% ethanol at -20 °C for 24 h. The cells 
were next incubated in dark for 30 min with 1 mg/mL ribonuclease A (RNase A; Sigma) 
and 10 fig/mL propidium iodide (PI; Sigma). Samples were analyzed for DNA content by 
measuring PI fluorescence on the Epics XL-MCL flow cytometer (Beckman Coulter, 
Miami, FL). Cells displaying hypodiploid DNA content were quantified and regarded as 
the apoptotic population. 
2.3 Determination of caspase activities 
Caspase-3 and caspase-9 activities were determined by using the fluorogenic peptide 
substrates, DEVD-AFC (50 i^M), and LEHD-AFC (100 |JM) (Calbiochem), respectively. 
Cell lysates from 1 x 10^  cells and substrates were mixed in a standard reaction buffer (20 
mM HEPES, 10% glycerol, 2 mM dithiothreitol (DTT), pH 7.5), and incubated for 1 hour 
at 37 The amount of enzyme-catalyzed AFC release was measured by a fluorescence 
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plate reader (Tecan, Grodig, Austria) with an excitation wavelength of 400 nm and an 
emission wavelength of 505 nm. Fluorescence values were converted into picomoles of 
AFC release by using a standard curve generated with free AFC. 
2.4 Western blotting 
2,4.1 Protein extraction and determination of protein concentration 
For preparation of whole cell lysates, cells were harvested and suspended for 30 minutes 
on ice in an extraction buffer (20 mM Tris-HCl at pH 8.0，150 mM NaCl, 5 mM EDTA, 
0.2% BSA, 1% Triton X-100) supplemented with protease inhibitors (BD Biosciences, 
San Jose, CA). Lysates were clarified by centrifugation at 4 °C for 15 minutes at 15 OOOg. 
The resulting supematants were frozen at -20 °C or used immediately. Aliquots of the 
supernatants were used for protein concentration determination by the standard 
bicinchoninic acid assay kit (Pierce, Rockford, IL). 
To obtain mitochondrial and cytosolic fractions, homogenates from leukemic cells 
were fractionated by the Cytosol-Mitochondria Fractionation kit (Calbiochem). Briefly�1 
X 1 (T cells were harvested and resuspended in cytosol extraction buffer supplemented 
with protease inhibitors for 10 minutes on ice, and disrupted using a Dounce homogenizer. 
Homogenates were then centrifuged at 700g at 4 °C for 10 minutes. The supematants 
were further centrifuged at 10 OOOg for 30 minutes at 4 The resulting supernatants 
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(cytosolic fraction) and pellets (mitochondrial fraction) were recovered. 
2.4.2 SDS'PAGE and immunodetection 
Samples (30 - 100 |ag protein) were denatured in Laemmli buffer and resolved on 10 
or 13% sodium docecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) minigels, 
followed by electrophoretic transfer to nitrocellulose membranes (Hybond ECL; 
Amersham, Buckinghamshire, UK). The membranes were blocked for 1 h in 
Tris-buffered saline with 0.1% Tween-20 containing 5% non-fat dry milk. 
Immunodetection was performed by overnight incubation at 4 °C with primary antibodies 
diluted in the same blocking buffer. Primary antibodies to PARP, caspase-3�caspase-9, 
BC1-XL, Bak, Bad, Bim, Bid, phospho-ERK (Thr-202/Tyr-204), ERK�phospho-JNK 
(Thr-183/Tyr-185), JNK, phospho-p38 (Thr-180/Tyr-182), p38, phospho-Akt (Ser-473), 
Akt, phospho-c-Jun (Ser-63), c-Jun and cytochrome c were obtained from Cell Signalling 
Technology, Beverly, MA. Antibodies to Bcl-2, Mcl-l, Bax, Bik and Nip-3 were 
purchased from BD Biosciences, while antibody to p-actin was obtained from Sigma. 
After extensive washing, the blots were probed with horseradish peroxidase-conjugated 
secondary antibodies (Cell Signalling Technology) for 1 hour at room temperature, and 
proteins were visualized by enhanced chemiluminescence (Cell Signalling Technology). 
Primary antibodies were employed at a 1:250 to 1:5000 dilution, and secondary 
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antibodies were employed at a 1:2000 dilution. 
2.5 Cell-free apoptosis reactions 
For preparation of S-100 cytosolic extracts, 5 x 10^  cells were collected and 
incubated for 10 minutes in ice-cold S-100 buffer (20 mM HEPES-KOH at pH 7.5, 10 
mM KCl, 1.5 mM MgCh, 1 mM EDTA, 1 mM EGTA, 1 mM DTT) supplemented with 
protease inhibitors. Cells were disrupted using a Dounce homogenizer, and centrifuged at 
lOOOg for 10 minutes at 4 Supematants were further centrifuged at 100 OOOg for 1 
hour, and the resulting supematants (S-100 fraction) were stored at -70 °C or used 
immediately. For cell-free caspase activation, S-100 cytosol (100 |ig) was incubated with 
1 mM dATP (deoxyadenosine triphosphate) and 4 fxM cytochrome c (Sigma) for 1 hour at 
30 Aliquots of reaction products were then collected for assessment of pro-caspase-3 
processing by Western blotting. 
2.6 Analysis of mitochondrial membrane potential 
Loss of mitochondrial membrane potential (A^m) was detected by using the 
potential-sensitive fluorescent probe, tetramethylrhodamine ethyl ester (TMRE; 
Molecular Probes, Eugene, OR). Treated or untreated cells were incubated with 25 nM 
TMRE for 15 minutes at 37 °C prior to analysis on a flow cytometer. As a positive control, 
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cells were incubated with 100 |a,M potential-disrupting agent, carbonyl cyanide 
3-chlorophenyIhydrazone (CCCP; Sigma) for 24 hours. Data are displayed as the 
percentage of cells with reduction in mitochondrial membrane potential. 
2.7 Transient transfection of Sup-Tl cells 
The Bcl-2 antisense oligonucleotide, that targets the first 6 codons of the opening 
reading frame of Bcl-2 mRNA, was purchased from Calbiochem. The full-length, wild 
type human BiniEL and Bax cDNA, which are cloned into the expression vector 
pCMV6-XL5, were obtained from Origene, Rockville, MD. Transient transfection of 
Sup-Tl cells was accomplished using Lipofectin reagent (Invitrogen, Carlsbad, CA) 
under serum-free conditions. Briefly, 2.5 x 10^  cells were transfected with either 3 |ig of 
Bcl-2 antisense oligonucleotide or 5 |ig of BimEL or Bax expression vector. After 24 hours 
of transfection, the medium was replaced with complete medium, and the cells were 
treated with or without etoposide for 24 hours. The cells were then harvested for analysis 
of gene expression, and processing of pro-caspase-3 and PARP by Western blotting. 
2.8 Reverse transcription-polymerase chain reaction (RT-PCR) 
2.8.1 RNA isolation 
Total RNA was isolated from leukemic cells by using TRIzol reagent (Invitrogen). 
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Briefly, the cells were pelleted by centrifugation, and lysed in TRIzol reagent for 5 
minutes. Chloroform (0.2 mL/mL TRIzol reagent) was then added to the homogenates, 
and the samples were mixed vigorously for 15 seconds. Subsequently, the mixture was 
centrifuged at 12 OOOg for 10 minutes at 4 After centrifugation, RNA in the aqueous 
phase was precipitated by mixing with isopropyl alcohol (0.5 mL/mL TRIzol reagent). 
The RNA pellet was washed with 75% ethanol�and issolved in RNase-free water. 
2.8.2 Synthesis of first-strand cDNA 
First-strand cDNA was synthesized by reverse transcription using the SuperScript 
First Strand Synthesis System (Invitrogen). Briefly, 2 |ig of DNase I-treated RNA was 
reversely transcribed for 1 hour at 42 in a reaction mix containing Ix reverse 
transcription buffer, 50 ng random hexamers�0.5 mM dNTPs, 5 mM MgCb, 10 mM DTT, 
20 U RNaseOUT RNase inhibitor and 50 U SuperScript II reverse transcriptase. The 
reaction was terminated at 70 for 15 minutes. Subsequently, 1 U RNase H was added 
to the samples to remove the RNA template. The cDNA was stored at -20 °C or used 
immediately for PGR. 
2.8.3 Polymerase Chain Reaction 
All PCR reagents were purchased from Amersham. The first-strand cDNA was 
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diluted and used as template in PCR reactions containing 0.8 jiM primers, 0.2 mM dNTPs, 
1.5 mM MgCli, Ix PCR buffer and 0.5 U Taq polymerase. The PCR reaction was 
subjected to 3 min denaturation at 96 followed by 25 cycles of amplification (94 °C, 
30 s; 55 30 s; 72 °C�60 s) and a final extension at 72 for 10 min. The gene-specific 
primer pairs were: Bax-sense (5'-CTG AGC AGA TCA TGA AGA CAG G-3') and 
Bax-antisense (5'-AAG TAG AAA AGG GCG ACA ACC-3,); Bcl-2-sense (5'-GAA 
TTC CAC TGT CAA GAA AGA GCA GT-3，) and Bcl-2-antisense (5'-GCT TTC GAA 
ATA TCA ACC ACA GCA TT-3')； Bim-sense (5'-ATG GCA A AG CAA CCT TCT 
GA-3') and Bim-antisense (5'-CGC ATA TCT GCA GGT TCA GCC-3')； 
GADPH-sense (5'-AAG ATC ATC AGC AAT GCC TCC-3，) and GADPH-antisense 
(5'-CCT GCT TCA CCA CCT TCT TGA-3’). PCR products were separated by 
electrophoresis in 1% agarose gels, and were visualized by ethidium bromide staining. 
2.9 Alkaline phosphatase digestion of Bim 
Cell lysates (50 |ig) were digested with 50 U of calf intestinal alkaline phosphatase 
(CIAP; Calbiochem) for 1 hour at 3 7 � C in a digestion buffer (50 mM Tris-HCl at pH 7.9, 
100 mM NaCl�10 mM MgCl2, 1 mM DTT) prior to Western blotting. 
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Chapter 3 Results 
3.1 The T-ALL cell line Sup-Tl is resistant to etoposide-induced apoptosis 
We first tested the response of a panel of established T-ALL cell lines, including 
HSB-2, MOLT-3 and Sup-Tl� to the commonly used anticancer drug, etoposide. Raji, a 
Burkitt lymphoma-derived cell line, which was previously shown to be resistant to 
etoposide (Sun et al.，2005) as well as to other chemotherapeutic agents (Kawabata et al, 
1999), was included as a control cell line. 
Leukemic cells treated with 1 |_iM of etoposide for 24 hours were subjected to flow 
cytometric evaluation of DNA content using propidium iodide staining. Despite the cell 
cycles had been deregulated, less than 10% apoptosis (hypodiploid population) was 
detected in Raji and Sup-Tl cells after 24 hours of treatment. In contrast, more than 80% 
apoptosis was detected in HSB-2 and MOLT-3 cells (Fig 3.1 and 3.2). 
To confirm these results, cell lysates from the leukemic cells were immunoblotted 
with specific antibody that recognizes full-length PARP and its cleaved form. 
Etoposide-triggered processing of intact PARP to its 89-kDa fragment was evident in 
MOLT-3 and HSB-2 cells but could not be detected in Raji and Sup-Tl cells, suggesting 
that etoposide is capable of inducing apoptosis in MOLT-3 and HSB-2 but not Raji and 
Sup-Tl cells (Fig. 3.3). 
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To ascertain whether apoptosis in Sup-Tl cells was merely delayed, we lengthened 
the incubation period to 48 hours. Results from flow cytometric analysis revealed that the 
response of the leukemic cells to etoposide was more or less the same upon an extended 
treatment period (Fig 3.4 and 3.5). Likewise, 5- and 10-fold increase in the dose of 
etoposide was still incapable of eliciting an apoptotic response in Sup-Tl cells. In Raji, 
although there was a dose-dependent increase of apoptosis (about 20% apoptosis when 
treated with 10 |iM etoposide), resistance to etoposide was still prominent, when 
compared with the cases in MOLT-3 and HSB-2 cells (Fig 3.6 and 3.7). 
Taken together, these data demonstrate that the T-ALL cell line Sup-Tl is 
completely resistant to etoposide-induced apoptosis. This prompted us to recruit Sup-Tl 
as a model cell line to unravel the possible resistance mechanisms of 
chemotherapy-induced apoptosis in T-ALL cells. 
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Fig. 3.1 Representative DNA histograms showing the response of leukemic 
cell lines to etoposide. 
Leukemic cells were incubated for 24 hours in the absence {control) or 
presence of 1 \iM etoposide, and subjected to flow cytometric analysis 
of DNA content using PI staining. Cells in gate C harbor hypodiploid 
DNA content, and they were defined as apoptotic cells; while cells in 
gate D harbor normal DNA content, and they were defined as 
non-apoptotic cells. Numerical data are shown in Fig. 3.2. The numbers 
in the x- and y-axes of the DNA histograms represent the relative 
fluorescence intensity and cell number, respectively. 
• . 
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Fig. 3.2 Numerical data showing the response of leukemic cell lines to 
etoposide. 
Leukemic cells were incubated for 24 hours in the absence ( • ) or 
presence ( • ) of 1 |iM etoposide, and subjected to flow cytometric 
analysis of DNA content using PI staining. Cells with hypodiploid DNA 
content were counted, and their numbers are expressed as a percentage 
of total population. Results are shown as mean values 士 S. D. (n = 3). 
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Fig. 3.3 Representative immunoblot showing the PARP status of leukemic 
cells in response to etoposide. 
Lysates from leukemic cells treated for 24 hours with or without 1 ^ iM 
etoposide were analyzed by Western blotting for the processing of 
PARP by using specific antibody, p-actin was used as a loading control. 
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Fig. 3.4 Representative DNA histograms showing the response of leukemic 
cell lines to an extended incubation period of etoposide. 
Leukemic cells were incubated in the absence {control) or presence of 1 
I^ M etoposide for 24 or 48 hours, and subjected to flow cytometric 
analysis of DNA content using PI staining. Cells in gate C harbor 
hypodiploid DNA content, and they were defined as apoptotic cells; 
while cells in gate D harbor normal DNA content, and they were 
defined as non-apoptotic cells. Numerical data are shown in Fig. 3.5. 
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Fig. 3.5 Numerical data showing the response of leukemic cell lines to an 
extended incubation period of etoposide. 
Leukemic cells were incubated in the absence ( • ) or presence of 1 |JM 
etoposide for 24 ( • ) or 48 hours (•)，and subjected to flow cytometric 
analysis of DNA content using PI staining. Cells with hypodiploid DNA 
content were counted, and their numbers are expressed as a percentage 
of total population. Results are shown as mean values 土 S. D. (n = 3). 
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Fig. 3.6 Representative DNA histograms showing the response of leukemic 
cell lines to higher doses of etoposide. 
Leukemic cells were incubated in the absence {control) or presence of 1， 
5 or 10 [lM etoposide for 24 hours, and subjected to flow cytometric 
analysis of DNA content using PI staining. Cells in gate C harbor 
hypodiploid DNA content, and they were defined as apoptotic cells; 
while cells in gate D harbor normal DNA content, and they were 
defined as non-apoptotic cells. Numerical data are shown in Fig. 3.7. 
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Fig. 3.7 Numerical data showing the response of leukemic cell lines to 
higher doses of etoposide. 
Leukemic cells were incubated in the absence ( • ) or presence of 1 
(•)，5 ( • ) or 10 nM (O) etoposide for 24 hours, and subjected to flow 
cytometric analysis of DNA content using PI staining. Cells with 
hypodiploid DNA content were counted, and their numbers are 
expressed as a percentage of total population. Results are shown as 
mean values 士 S. D. (n = 3). 
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3.2 Sup-Tl cells are resistant to etoposide-induced caspase activation 
Etoposide exerts its anticancer effect by inducing DNA damage and activating the 
mitochondrial-dependent apoptosis pathway (Robertson et al, 2000). Thus, we believed 
that the resistance to etoposide-induced apoptosis in Sup-Tl cells is attributed to 
impairment of the effectors or regulators involved in the mitochondrial pathway 
signalling. 
Activation of caspases is crucial to the etoposide-induced apoptosis in Jurkat T cells 
as well as in other cell types (Robertson et al” 2000; Lin et al, 2004). To test whether the 
same can be applied to our panel of T-ALL cell lines, the leukemic cells were 
preincubated with 50 |iM z-VAD-fmk (a pan-caspase inhibitor) for 1 hour prior to the 
etoposide treatment. Results from flow cytometric analysis showed that apoptosis in the 
etoposide-sensitive MOLT-3 and HSB-2 cells was significantly blocked by preincubation 
with z-VAD-fmk, from more than 80% to less than 15% (Fig. 3.8 and 3.9), suggesting 
that caspases are playing a critical role in the etoposide-mediated apoptosis in the T-ALL 
cells. Therefore, the resistance to etoposide-induced apoptosis in Sup-Tl cells is likely 
due to defective caspase activation. 
To investigate whether Sup-Tl cells are resistant to etoposide-induced caspase 
activation, cell lysates from the leukemic cells were immimoblotted with specific 
antibodies against caspase-3 and caspase-9. Etoposide-triggered processing of 
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pro-caspase-3 into the pi7 active subunit was readily detected in MOLT-3 and HSB-2 
cells (Fig. 3.10, top panel). Concomitant processing of pro-caspase-9 into its p35 and p37 
active fragments was also evident in MOLT-3 and HSB-2 extracts (Fig. 3.10, bottom 
panel). However, processing of pro-caspase-3 and procaspase-9 were absent in the 
etoposide-treated Raji and Sup-Tl cells. 
To verify these data, the cells treated with etoposide were subjected to measurement 
of caspase-3 and caspase-9 activities according to specific cleavage of the fluorescent 
substrates Ac-DEVD-AFC and Ac-LEHD-AFC, respectively. The results showed that 
neither Ac-DEVD-AFC (Fig. 3.11, top panel) nor Ac-LEHD-AFC cleavage (Fig. 3.11, 
bottom panel) could be detected in the etoposide-treated Raji and Sup-Tl cells; whereas, 
cleavage of these synthetic substrates were readily detected in HSB-2 and MOLT-3 cells 
upon the etoposide treatment. Taken together, these data demonstrate that Sup-Tl cells 
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Fig. 3.8 Representative DNA histograms showing the effect of pan-caspase 
inhibitor preincubation on etoposide-induced apoptosis in leukemic 
cell lines. 
Leukemic cells preincubated for 1 hour in the absence {control) or 
presence of 50 jaM the pan-caspase inhibitor, z-VAD-fmk, were treated 
with 1 |iM etoposide for 24 hours, and subjected to flow cytometric 
analysis of DNA content using PI staining. Cells in gate C harbor 
hypodiploid DNA content, and they were defined as apoptotic cells; 
while cells in gate D harbor normal DNA content, and they were 
defined as non-apoptotic cells. Numerical data are shown in Fig. 3.9. 
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Fig. 3.9 Numerical data showing the effect of pan-caspase inhibitor 
preincubation on etoposide-induced apoptosis in leukemic cell lines. 
Leukemic cells preincubated for 1 hour in the absence ( • ) or presence 
( • ) of 50 jiM the pan-caspase inhibitor, z-VAD-fmk, were treated with 
1 |iM etoposide for 24 hours, and subjected to flow cytometric analysis 
of DNA content using PI staining. ( • ) indicates control cells without 
pan-caspase inhibitor or etoposide treatment. Cells with hypodiploid 
DNA content were counted, and their numbers are expressed as a 
percentage of total population. Results are shown as mean values 士 S. 
D. (n = 3). 
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Fig. 3.10 Representative immunoblots showing the status of caspase-3 and 
caspase-9 of leukemic cells in response to etoposide. 
Lysates from leukemic cells treated for 24 hours with or without 1 pM 
etoposide were analyzed by Western blotting for the processing of 





^ I 3 5 � 
• I S 30 - 口 Control r 
« « • Etoposide I I H 丁 
«« 25 - • 
• • • 
J J 
0 [ i J B I _ _ , _ _ n ^ z ^ M _ _ , _ _ c t i B I _ _ , _ _ c J B _ _ , 
Raji Sup-Tl MOLT-3 HSB-2 
-A 2 5 � 
I 
C 
S 20 - T 
^ J 15 - • 
9 2 • T 
I I 
3 0 r ^ . r — ^ . I • . I • . 
Raji Sup-Tl MOLT-3 HSB-2 
Fig. 3.11 Graphs showing the effect of etoposide on caspase-3 and caspase-9 
activity in leukemic cell lines. 
Cells treated for 24 hours with 1 \iM etoposide were harvested for 
measurement of caspase-3 (top panel) and caspase-9 activity {bottom 
panel) according to specific cleavage of the fluorescent substrates 
DEVD-AFC and LEHD-AFC, respectively. Data are shown as mean 
values 土 S. D. (n = 3)，and depicted as pmol AFC release per minute. 
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3.3 Sup-Tl cells are insusceptible to etoposide-induced mitochondrial alterations 
Etoposide triggers mitochondrial release of cytochrome c in cancer cells, resulting in 
activation of the caspase cascade and induction of apoptosis (Robertson et al., 2000; Lin 
et al, 2004). To investigate whether etoposide treatment of T-ALL cells could induce 
mitochondrial release of cytochrome c, homogenates of T-ALL cells were separated into 
cytosolic and mitochondrial fractions, and subjected to detection of cytochrome c by 
Western blotting. As expected, etoposide triggered mitochondrial release of cytochrome c 
in MOLT-3 and HSB-2 cells, but not in Sup-Tl cells (Fig. 3.12). Therefore, defective 
caspase-3 and caspase-9 activation in the Sup-Tl cell line is likely attributed to the 
absence of mitochondrial cytochrome c release. 
We then used a cell-free system to further evaluate whether Sup-Tl cells are capable 
of promoting cytochrome c-dependent caspase activation. To this end�exogenous 
cytochrome c was added to S-100 cytosolic extracts derived from Raji and the T-ALL cell 
lines. Processing of pro-caspase-3 into the pi7 active fragment was readily detected in the 
etoposide-sensitive HSB-2 and MOLT-3 cells, as well as in the etoposide-resistant Sup-Tl 
cells (Fig. 3.13). Thus, defective caspase activation in Sup-Tl cells is due to the absence 
of mitochondrial cytochrome c release. These data also indicate that the death signalling 
downstream of mitochondria in Sup-Tl cells is robust. In Raji cells, despite etoposide 
could induce mitochondrial release of cytochrome c (Fig. 3.12), results from cell-free 
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apoptosis reactions showed that addition of exogenous cytochrome c could not restore 
caspase activation (Fig. 3.13). These observations are consistent with those published in a 
recent report, which clearly showed that the resistance to etoposide-induced apoptosis in 
Raji cells is blocked downstream of cytochrome c release, yet upstream of caspase-3 
activation (Sun et al, 2005). 
To further delineate the apoptosis defect in Sup-Tl cells, we tested whether 
etoposide could dissipate the mitochondrial membrane potential (A中m) in T-ALL cell 
lines by flow cytometry using a potential-sensitive fluorescent probe, TMRE. 
Etoposide-triggered mitochondrial depolarization was evident in HSB-2 and MOLT-3 but 
not Sup-Tl cells (Fig. 3.14). Treatment with an uncoupling agent, CCCP, however, 
dissipated the mitochondrial membrane potential in Sup-Tl cells (Fig. 3.14). Altogether, 
these data imply that the defective caspase activation in Sup-Tl cell line is ascribed to its 
insusceptibility to the etoposide-induced mitochondrial alterations. 
47 
. Chapter 1 
Raji Sup-Tl MOLT-3 HSB-2 
(kDa) 
Etoposide - + - + - + - + 
cytosolic cyt c - . lUiir . j M l l - 15 
mitochondrial cyt c - | | | | | ^ ^ ^ ^ ^ H l “ ^^  
P-actin 一 mmmm mam mmm mm^'-mm^ - 42 
Fig. 3.12 Representative immunoblots showing the effect of etoposide on the 
mitochondrial release of cytochrome c in leukemic cell lines. 
Homogenates from the leukemic cells treated for 24 hours with or 
without 1 }j,M etoposide were separated into cytosolic and mitochondrial 
fractions. The release of cytochrome c (cyt c) was evaluated by 
immunoblotting of cytosolic versus mitochondrial extracts using a 
specific antibody. (3-actin was used as a loading control for the cytosolic 
fractions. 
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Fig. 3.13 Representative immunoblots showing the cytochrome c-dependent 
activation of pro-caspase-3 in leukemic cell lines. 
S-100 cytosols were prepared from the leukemic cells, and exogenous 
dATP and cytochrome c (dATP/cyt c) were introduced to initiate 
caspase activation. Processing of pro-caspase-3 was determined by 
Western blotting. 
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Fig. 3.14 Representative histograms showing the etoposide-triggered 
dissipation of mitochondrial membrane potential in leukemic cell 
lines. 
Leukemic cells treated for 24 hours with or without 1 |iM etoposide 
were subjected to flow cytometric analysis of mitochondrial membrane 
potential using a potential-sensitive probe, TMRE. CCCP was used as a 
positive control for membrane depolarization. The percentages of cells 
with reduction in mitochondrial membrane potential are shown. 
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3.4 BiniEL is required for etoposide-induced apoptosis in Sup-Tl cells 
Apoptosis that proceeds via the mitochondrial pathway involves permeabilization of 
the outer mitochondrial membrane, which is responsible for the release of cytochrome c 
and other apoptogenic molecules. This essential step is regulated by proteins of the Bcl-2 
family (Green, 2006). Abnormal expression or malfunction of these proteins has been 
associated with the acquirement of resistance to apoptosis in tumour cells (Igney and 
Krammer, 2002; Kaufmann and Vaux, 2003). 
To explore whether the chemoresistance in Sup-Tl cells could be explained by 
altered expression of the Bcl-2 family members, we first determined the protein levels of 
10 better characterized Bcl-2 family members in the T-ALL cells by Western blotting. 
When their expression levels in the Sup-Tl cells were compared with those in the 
etoposide-sensitive HSB-2 and MOLT-3 cells, a marked elevation of the anti-apoptotic 
Bcl-2 was observed (Fig. 3.15). Moreover, expression levels of the pro-apoptotic member 
Bax and the extra-long isoform of pro-apoptotic Bim (BiniEL) were apparently reduced in 
the Sup-Tl cells (Fig. 3.15). However, the levels of anti-apoptotic members BC1-XL and 
Mcl-l, as well as the pro-apoptotic members Bak, Bad, Bik, Bid and Nip-3 in Sup-Tl 
cells were not differed from the etoposide-sensitive T-ALL cells (Fig. 3.15). Hence, it 
appeared that caspase activation and apoptosis in the Sup-Tl cell line might be impeded 
at least partially by elevated level of Bcl-2 and subthreshold levels of Bax and BiniEL-
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We next considered if the altered expression levels of Bcl-2, Bax and BiniEL render 
the Sup-Tl cells resistant to the etoposide-induced apoptosis. To address this question, we 
investigated whether silencing of Bcl-2 as well as enforced expression of Bax or BimEL 
could restore sensitivity to etoposide-induced apoptosis in the Sup-Tl cells. Results from 
the gene silencing experiments showed that transfection of a Bcl-2 antisense 
oligonucleotide into the Sup-Tl cells significantly reduced the protein level of Bcl-2 (Fig. 
3.16 a, lane 1 V5 lane 3), but not in the cells transfected with the corresponding, missense 
oligonucleotide (Fig. 3.16 a, lane 2). However, the reduced level of Bcl-2 could not 
resensitize the Sup-Tl cells to the etoposide-induced caspase-3 activation (Fig 3.16 b, 
lane 4 vs lane 5) and the consequent apoptosis, as judged by PARP cleavage (Fig. 3.16 c, 
lane 4 vs lane 5). Transient transfection of a wild-type Bax expression vector into the 
Sup-Tl cells had elevated the protein level of Bax (Fig. 3.17 a, lane 1 lane 3). Despite 
slight increases in the levels of active caspase-3 (pi7; Fig. 3.17 b, lane 4 vs lane 5) and 
cleaved PARP (p89; Fig. 3.17 c, lane 4 vs lane 5) could be detected in the 
Bax-overexpressing cells upon the etoposide treatment, the levels of these fragments, 
however, were not significantly different from the cells transfected with an empty vector 
(Fig. 3.17 b and c, lane 2) or a Bax expression vector (Fig. 3.17 b and c� lane 3). This 
suggested that an enhanced expression of Bax still could not restore the 
etoposide-induced apoptosis in the Sup-Tl cells. We then tested the ability of 
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overexpressed, wild type BiniEL to restore sensitivity of the Sup-Tl cells to the 
etoposide-induced apoptosis. Transient transfection of a BimEL expression vector into the 
Sup-Tl cells resulted in an elevation of BimEL protein levels (Fig. 3.18 a, lanel vs lane 3) 
that was not observed in the cells transfected with an empty vector (Fig. 3.18 a, lanel 
lane 2). Indeed, overproduction of BimEL in the Sup-Tl cells resulted in an elevated level 
of apoptosis, indicated by increased processing of pro-caspase-3 (Fig. 3.18 b, lane2 vs 
lane 3) and PARP (Fig. 3.18 c, lane2 vs lane 3). Strikingly, the pi7 active subunit of 
caspase-3 and the p89 cleaved fragment of PARP were most readily detected in the 
BiniEL-overexpressing cells following the etoposide treatment (Fig. 3.18 b and c, lane 5), 
indicating that the enhanced level of BimEL could resensitize the Sup-Tl cells to the 
etoposide-induced apoptosis. Taken together, these data clearly reveal a critical role of 
BimEL in determining the sensitivity to etoposide-induced apoptosis in Sup-Tl cells. 
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Fig. 3.15 Representative immunoblots showing the expression levels of Bcl-2 
family proteins in leukemic cell lines. 
Lysates from the leukemic cells were analyzed for protein levels of 10 
Bcl-2 family members by Western blotting using specific antibodies. 
(3-actin was used as a loading control. 
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Fig. 3.16 Representative immunoblots showing the effect of Bcl-2 silencing on 
the etoposide-induced apoptosis in Sup-Tl cells. 
Sup-Tl cells were either mock-transfected (lane 1) or transfected with a 
Bcl-2-specfic antisense oligonucleotide {lane 5), and treated with 1 \M 
etoposide for 24 hours (Janes 4 and 5). After treatment, cells were 
harvested, and the lysates were analyzed for Bcl-2 level as well as 
processing of pro-caspase-3 and PARP by Western blotting. Cells 
transfected with a control oligonucleotide {lane 2) that minimally 
reduced Bcl-2 expression were included as a negative control, p-actin 
was used as a loading control. 
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Fig. 3.17 Representative immunoblots showing the effect of Bax 
overexpression on etoposide-induced apoptosis in Sup-Tl cells. 
Sup-Tl cells were either mock-transfected (fane 1) or transfected with a 
wild-type Bax expression vector (Jane 5), and treated with 1 jxM 
etoposide for 24 hours {lanes 4 and 5). After treatment, the cells were 
harvested, and the lysates were analyzed for Bax level as well as 
processing of pro-caspase-3 and PARP by Western blotting. The cells 
transfected with an empty vector {lane 2) were included as a negative 
control. P-actin was used as a loading control. 
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Fig. 3.18 Representative immunoblots showing the effect of BiniEL 
overexpression on etoposide-induced apoptosis in Sup-Tl cells. 
Sup-Tl cells were either mock-transfected (lane I) or transfected with a 
wild-type BiniEL expression vector (Jane J), and treated with 1 |iM 
etoposide for 24 hours {lanes 4 and 5). After treatment, the cells were 
harvested, and the lysates were analyzed for BiniEL level as well as 
processing of pro-caspase-3 and PARP by Western blotting. The cells 
transfected with an empty vector {lane 2) were included as a negative 
control, p-actin was used as a loading control. 
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3.5 The reduced level of BiniEL in Sup-Tl cells is owing to the presence of 
constitutively active JNK 
Bim expression can be regulated at either transcriptional (Dijkers et al, 2000; Putcha 
et al., 2001; Stahl et al, 2002) or post-transcriptional level (Biswas and Greene, 2002; Lei 
and Davis, 2003; Luciano et al, 2003; Qi et al., 2006). To investigate whether the low 
level of Bim protein in Sup-Tl cells (Fig. 3.15) can be explained by reduced transcription 
of the Bim gene, mRNA level corresponding to the BiniEL isoform was determined by 
RT-PCR. We found that BiniEL was highly expressed in Sup-Tl cells, and its expression 
level was comparable to those in MOLT-3 and HSB-2 cells (Fig. 3.19)，suggesting that 
BiiTiEL expression may be regulated by some post-transcriptional mechanisms in Sup-Tl 
cells. The mRNA levels of Bcl-2 and Bax in Sup-Tl cells, on the contrary, were found 
similar to those of their respective protein products (Fig. 3.15 and 3.19), indicating that 
the expression levels of these two proteins are determined transcriptionally. 
The proteosome pathway has been shown previously to be involved in the 
degradation of Bim following its phosphorylation (Luciano et al., 2003; Qi et al., 2006). 
Thus, the apparent low level of BiniEL protein in Sup-Tl cells may possibly be resulted 
from the same pathway. To address this question, Sup-Tl cells were treated in the 
presence or absence of the proteosome inhibitor, MG-132. Western blot analysis revealed 
that BiniEL could hardly be detected in the absence of proteosome inhibitor (Fig. 3.20, 
t 
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lane I). Incubation with MG-132, however, significantly increased the protein level of 
BimEL in Sup-Tl cells (Fig. 3.20，lane 2). In addition, treatment with proteosome 
inhibitor resulted in mobility shift of the BiniEL protein, evidenced by the presence of 
immunoreactive BiniEL with higher molecular masses (Fig. 3.20, lane 2). To determine 
whether the observed mobility shift was due to phosphorylation of the BimEL protein, the 
cell lysate from Sup-Tl cells treated with the proteosome inhibitor was digested with calf 
intestinal alkaline phosphatase (CIAP). Digestion with CIAP resulted in a partial increase 
in the mobility of BimEL species (Fig. 3.20, lane 3), when compared with the undigested 
sample (Fig. 3.20，lanes 2). Taken together, these data suggest that the newly synthesized 
BimEL protein in Sup-Tl cells is phosphorylated and form different species. This serves as 
a signal for degradation through the proteosome pathway, thereby resulting in the loss of 
its expression. 
Bim has been reported to be a target for ERK (Ley et al” 2003; Luciano et al,, 
2003), JNK (Lei and Davis, 2003; Putcha et al, 2003)，p38 (Cai et al, 2006) and Akt 
phosphorylation (Qi et al., 2006). To investigate whether these protein kinases are also 
responsible for modulation of BiniEL expression in Sup-Tl cells, we first determined their 
activities by using antibodies that only recognize the phosphorylated, active forms of 
these kinases. Western blot analysis showed that all of these kinases were highly 
expressed in the Sup-Tl cells (Fig. 3.21). However, only Akt and JNK were found 
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constitutively active in the Sup-Tl cells (Fig. 3.21). To explore the potential roles of these 
protein kinases in BiniEL degradation, Sup-Tl cells treated with specific inhibitors of the 
ERK (PD98059，U0126), JNK (SP600125), p38 (SB203580) and Akt (LY294002, 
wortmannin) pathways were subjected to detection of endogenous BiniEL by Western 
blotting. We found that the expression of BiniEL could not be restored by the PI3-K 
inhibitor, LY294002 or wortmannin. Similar results were obtained from the cells treated 
with the MEK inhibitor, PD98059 or U0126, or the p38 inhibitor SB203580 (Fig. 3.22). 
Surprisingly, treatment of Sup-Tl cells with the JNK inhibitor SP600125 significantly 
elevated the Bim protein level (Fig. 3.22), suggesting that the degradation of BiniEL in 
Sup-Tl cells is mediated by JNK-dependent events. 
BiniEL was found crucial for the etoposide-induced apoptosis in Sup-Tl cells (Fig. 
3.18). Then, suppression of its expression by some JNK-mediated events is very likely to 
be the reason that renders this cell line resistant to the etoposide-induced apoptosis. To 
address this question, we investigated whether the JNK inhibitor SP600125 could 
resensitize Sup-Tl cells to the etoposide-induced apoptosis. The results revealed that the 
JNK activity in Sup-Tl cells was reduced by the SP600125 treatment, indicated by the 
decreased level of active, phosphorylated c-Jun (Fig. 3.23 a, lane 1 vs lane 2). Again, 
BimEL expression was significantly elevated when the JNK activity was inhibited (Fig 
3.23 c，lane 1 vs lane 2), but the increased level of BiniEL did not result in caspase-3 
60 
. Chapter 1 
activation and PARP cleavage (Fig 3.23 d and e，lane 2). However, the pi7 active subunit 
of caspase-3 and cleaved fragment of PARP were readily detected in cells preincubated 
with SP600125 followed by etoposide treatment (Fig. 3.23 d and e, lane 3 vs lane 4), 
indicating that suppression of JNK activity can resensitize Sup-Tl cells to the 
etoposide-induced apoptosis. Taken together, our results indicate that the resistance to 
etoposide-induced apoptosis in Sup-Tl cells is due to the presence of constitutively JNK. 
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Raji Sup-Tl MOLT-3 HSB-2 
GADPH 
Fig. 3.19 Representative images showing the mRNA levels of Bcl-2, Bax and 
Bim in leukemic cell lines. 
Total mRNA was extracted from the leukemic cells, and the mRNA 
levels of Bcl-2, Bax and BiniEL were assessed by RT-PCR. GADPH was 
used as a loading control. 
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Fig. 3.20 Representative immunoblots showing the effect of proteosome 
inhibitor on Bim expression in Sup-Tl cells. 
Sup-Tl cells were cultured for 24 hours in the absence (Jane 1) or 
presence of 50 |iM proteosome inhibitor, MG-132 {lane 2). After 
treatment, the cells were harvested, and the lysates were analyzed for 
BiniEL protein level by Western blotting. Aliquot of the lysate from cells 
treated with MG-132 was digested with calf intestinal alkaline 
phosphatase (CIAP, lane J) for 1 hour, prior to the Western blot 
analysis, p-actin was used as a loading control. 
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Fig. 3.21 Representative immunoblots showing the activities of protein 
kinases in leukemic cell lines. 
Phosphorylated and active forms of ERK, JNK, p-38 and Akt in the 
leukemic cells were determined by Western blotting using 
phospho-specific antibodies. Blots were also analyzed for the total 
protein levels of each kinase, p-actin was used as a loading control. 
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Fig. 3.22 Representative immunoblots showing the effect of different protein 
kinase inhibitors on Bim expression in Sup-Tl cells. 
Sup-Tl cells were incubated for 24 hours with either DMSO {control), 
10 jiM U0126, 10 \M PD98509, 10 |iM SP600125, 15 [iM SB203580, 
50 |iM LY294002, or 100 nM wortmannin. The cell lysates were 
analyzed for Bim protein levels by Western blotting, p-actin was used as 
a loading control. 
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Fig. 3.23 Representative immunoblots showing the effect of JNK inhibitor on 
etoposide-induced apoptosis in Sup-Tl cells. 
Sup-Tl cells were preincubated in the absence (Jane 1) or presence 
{lane 2) of 10 \iM JNK inhibitor, SP600125, for one hour and then 
treated with {lane 4) or without (Jane 3) 1 |xM etoposide for 24 hours. 
The inhibitor remained present throughout the etoposide treatment. The 
cell lysates were then analyzed for p-c-Jun, c-Jun and BiniEL levels as 
well as processing of pro-caspase-3 and PARP by Western blotting, 
p-actin was used as a loading control. 
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Chapter 4 Discussion 
Historically, patients with T-cell acute lymphoblastic leukemia (T-ALL) have been 
reported to have a worse prognosis than patients with B-lineage ALL. Pieters et al. 
showed that T-ALL blasts have demonstrated greater in vitro resistance to standard 
chemotherapeutic agents, such as glucocorticoids, vincristine, and asparaginase (Pieters et 
al., 1993; Pieters et al., 1998). Relative prednisone resistance was also demonstrated in 
vivo on the Berlin-Frankfurt-Muenster protocol, in which 36% of T-ALL patients had 
demonstrated poor peripheral blood response after the prednisone treatment, compared 
with 5% of patients with ALL of the B-lineage (Schrappe et al, 2000). In recent clinical 
studies, however, the event-free survival rates for patients with T-ALL treated on the 
DFCI ALL Consortium protocols were found comparable to the patients with B-lineage 
ALL (Silverman et al., 2000). Unique features of these protocols that might have 
contributed to the improved outcome of T-ALL patients include consolidation with 
doxorubicin and weekly high-dose asparaginase, as well as frequent pulses of high-dose 
corticosteroids. 
Despite the adverse risk associated with T-lineage ALL has progressively been 
overwhelmed by intensive chemotherapeutic regimens, approximately 20% of the patients 
with T-ALL continue to fail the therapy. Higher rate of induction failure and early relapse 
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in these patients suggest that their blast cells are more inherently resistant to conventional 
chemotherapeutic agents. Further augmentation of the currently used intensive 
chemotherapeutic regimens may not be warranted because of the likelihood of significant 
adverse effects. Thus, the identification of additional prognostic variables and 
chemoresistance mechanisms that can be used for more precise tailored-therapy is of top 
priority. Evaluation of the underlying molecular mechanisms determining response or 
resistance not only enables clinicians to define prognostic markers, but also facilitates the 
design of molecularly targeted agents potentially reversing the causative lesion. 
Unfortunately, the cause of treatment failure in T-ALL patients is still largely 
unknown. Only a few candidate genes have been implicated in determining the sensitivity 
of T-ALL cells to chemotherapeutic agents. Steinbach et al. showed that higher level of 
multidrug resistance-associated protein 3 (MRP-3) in T-ALL patients is associated with a 
poor in vivo response to prednisone (Steinbach et al., 2003). Ramakers-van Woerden et al. 
demonstrated that pi6 homozygously deleted T-ALL cases have a significant worse 
disease-free survival. However, the pi6 gene deletion was only correlated with the in 
vitro resistance to dexamethasone and prednisolone, among the 10 drugs tested 
(Ramakers-van Woerden et al., 2001). A more recent study showed that a T-ALL cell line, 
MOLT-4, having aberrant Notch-1 signaling is chemoresistant (Mungamuri et al” 2006). 
Aberrations in apoptotic pathways have been detected in a variety of cancers, 
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suggesting that loss of the ability of cells to undergo apoptosis may contribute to 
carcinogenesis. Because cancer therapies such as radiation, glucocorticoids, and 
chemotherapeutic drugs exert their beneficial effects, at least in part, by inducing 
apoptosis in the cancer cells, the same aberrations in apoptotic pathways would be 
predicted to contribute to resistance (Kauftnann and Vaux，2003). In the present study, we 
therefore speculated that defective apoptosis could render T-ALL cells resistant to 
chemotherapeutic agents. 
By studying the cellular responses to an apoptogenic drug, etoposide, we identified 
an apoptosis-resistant T-ALL cell line, Sup-Tl. Thus, we recruited Sup-Tl as a model 
cell line to study the possible mechanisms of resistance to etoposide-induced apoptosis in 
T-ALL cells. Flow cytometric analysis revealed that etoposide treatment apparently 
induced cell cycle arrest in Sup-Tl cells. However, cell cycle arrest and apoptosis are not 
sequential events in the Sup-Tl model, implying that resistance to etoposide in Sup-Tl 
cells is linked to defective apoptosis but not events associated with the cell cycle. Further 
experiments showed that Sup-Tl cells were deficient in the etoposide-induced activation 
of caspases and mitochondrial cytochrome c release (Fig. 3.10，3.11 and 3.12). However, 
addition of exogenous cytochrome c in the cell-free apoptosis reactions induced 
prominent caspase-3 activation (Fig. 3.13). These findings suggest that the 
chemoresistance observed in Sup-Tl cells is due to its insusceptibility to drug-induced 
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mitochondrial alterations. 
Proteins in the Bcl-2 family are the central regulators of apoptosis. Abnormal 
expressions of these Bcl-2 family proteins have been implicated in the development of 
chemoresistance in tumor cells. Overexpressions of anti-apoptotic members Bcl-2, BC1-XL 
and Mcl-l have been shown to confer resistance to a variety of anticancer agents. Besides, 
tumors can also acquire resistance by downregulating expressions of the proapoptotic 
members Bax and Bid (Igney and Krammer, 2002). Analysis of expression of the Bcl-2 
family proteins in this study revealed that the levels of Bax, Bcl-2 and Bim in Sup-Tl 
cells were differed from those in the etoposide-sensitive T-ALL cell lines (Fig. 3.15). 
Indeed, our data obtained in the Sup-Tl model show that the defective apoptosis and 
activation of caspases are linked to a lack of expression of Bim, a pro-apoptotic member 
of the Bcl-2 family proteins. Transient transfection of BimEL cDNA into resistant Sup-Tl 
cells yielded elevated level of Bim protein and restored their sensitivity to the 
etoposide-induced apoptosis (Fig. 3.18). This provides direct evidence that Bim is an 
important determinant for the sensitivity of T-ALL Sup-Tl cells to the etoposide-induced 
apoptosis. 
Bim, the Bcl-2 interacting mediator of cell death, is expressed by a wide variety of 
tissues, but is most prominently expressed by cells of hematopoietic origin (O'Reilly et 
al., 2000). Although multiple Bim mRNA transcripts have been described that are 
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generated by alternative splicing (0'Conner et al., 1998; Bouillet et al., 2001; Marani et 
al., 2002), most tissues express one predominant isoform of Bim as determined by 
Western blotting analysis, termed BimEL. Several lines of evidence have shown that Bim 
is critical for apoptosis in certain types of cells. Gene-knockout study revealed that Bim is 
a principal regulator of hematopoietic homeostasis (Bouillet et al., 1999). In its absence, 
leukocyte numbers rise and plasma-cell accumulation provokes the onset of an 
autoimmune disease. This onset occurs because Bim is essential for the elimination of 
autoreactive lymphocytes by apoptosis (Bouillet et al., 2002). Putcha et al. demonstrated 
that induction of Bim is also critical for apoptosis in neurons (Putcha et al., 2001). 
Moreover, Bim is required for apoptosis induced by paclitaxel, dexamethasone, and 
histone deacetylase inhibitors (Strasser, 2005; Tan et al” 2005; Zhao et al., 2005). In 
T-ALL cells, Bim induction was found essential for glucocorticoid-induced apoptosis (Lu 
et al., 2006). In the current study, we provide the first evidence showing that lack of Bim 
expression could render T-ALL cells resistant to the etoposide-induced apoptosis. 
Under conditions that promote cell growth, Bim is bound to dynein light chain LC8 
of the microtubular motor complex, and is sequestered away from other Bcl-2 family 
members (Puthalakath et al” 1999). Following a pro-apoptotic stimulus, however, Bim 
localizes to the mitochondria, where it initiates the mitochondrial cell death pathway by 
either directly activating Bax-like proteins (Marani et al., 2002; Liu et al., 2003) or by 
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binding to the pro-survival Bcl-2 family members and thereby releasing the Bax-like 
proteins (Terradillos et al, 2002; Yamaguchi and Wang, 2002; Wilson-Annan et al., 
2003). As silencing of Bcl-2 did not resensitize Sup-Tl cells to the etoposide-induced 
apoptosis (Fig. 3.16)，and Sup-Tl cells do not express Bax (Fig. 3.15), we believe that the 
levels of Bim in Sup-Tl cells is insufficient to neutralize the anti-apoptotic actions of 
Mcl-L or BC1-XL, thereby hindering the release of mitochondrial cytochrome c and the 
consequent apoptotic events. 
Expression levels of BH3-only proteins are key determinants of cellular survival and 
are therefore under stringent control. Transcriptional and post-translational regulatory 
mechanisms have previously been described in the control of Bim expression levels. 
Transcriptional control of Bim appears to be complex, as different groups have reported 
different modes of regulation. Growth factor withdrawal-induced up-regulation of Bim 
expression was shown to require JNK activation in neurons (Harris and Johnson, 2001; 
Putcha et al., 2001) but depended on the forkhead transcription factor FKHR-Ll in 
hematopoetic cells (Dijkers et cd., 2000). Other studies with hematopoetic cell lines have 
indicated that cytokine stimulation represses Bim expression through activation of the 
mitogen-activated protein kinase pathway or the phosphatidylinositol 3’ kinase (Shinjyo 
et al., 2001). However, the lack of Bim expression in Sup-Tl cells is not likely regulated 
transcriptionally, as significant level of Bim mRNA was detected (Fig. 3.19), suggesting 
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that the low level of Bim protein in Sup-Tl cells is a consequence of post-transcriptional 
events. 
Ubiquitin-mediated degradation of Bim through the proteasomal pathway has 
recently emerged as a post-translational mechanism controlling cellular Bim level. In the 
different cellular models studied, the loss of Bim protein could be blocked by proteosome 
inhibitor MG-132 (Luciano et al.’ 2003). Furthermore, multiple ubiquitinated forms of 
Bim protein were demonstrated in the presence of proteosome inhibitors (Akiyama et al.’ 
2003), implicating the involvement of ubiquitin-proteosomal pathway in Bim degradation. 
In agreement with these studies, we showed that the level of BiniEL in Sup-Tl cells was 
significantly restored after incubation with MG-132 (Fig. 3.20). Thus, the newly 
synthesized BiniEL in Sup-Tl cells is rapidly targeted to the proteosome and degraded, 
therefore resulting in the lack of its expression. 
By Western blotting, multiple bands of immunoreactive BimEL species were detected 
in Sup-Tl cells following treatment with MG-132, and at least two of which were 
sensitive to phosphatase digestion (Fig. 3.20), suggesting that BiniEL had been 
phosphorylated at multiple sites. This finding is in line with the results of two previous 
studies in which the number of BimEL species was examined by two-dimensional gel 
electrophoresis (Seward et al” 2003; Ley at al, 2004). For example, it was shown that the 
BimEL immunoprecipitated from ^^P-labeled murine HT-2 or Ball7 lymphocytes could be 
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separated into at least four ^^P-labeled forms (Seward et al, 2003). Similar results were 
obtained in CCL39 fibroblasts, where addition of the fetal bovine serum to serum-starved 
cells resulted in the appearance of three phosphorylated forms of immunoreactive BiiriEL 
(Ley at al., 2004). Of note, our data demonstrated that some of the BiniEL species with 
higher molecular mass were not sensitive to phosphatase digestion (Fig.3.20). These data 
imply that, apart from phosphorylation, BiiriEL is also subjected to other types of 
modification that targeting it to the proteosome. 
The role of the ERK pathway in Bim phosphorylation has been intensively 
investigated. The fetal bovine serum-induced appearance of multiple forms of BiniEL in 
CCL39 cells was shown to be sensitive to the ERK 1/2 pathway inhibitor, PD184352, 
suggesting that multiple ERK phosphorylation sites exist in BiniEL (Ley et al., 2004). 
Studies in the IL-3-dependent murine pro-B cell line, FL5.12, demonstrated that when 
IL-3 was added back to the cytokine-deprived cells, there was a rapid shift in the mobility 
of BiiriEL to higher molecular weight forms (Harada et al” 2004). Further, six BiniEL 
mutants were generated by alanine substitution of putative ERK phosphorylation sites, 
and tested for their ability to be phosphorylated in vivo. Three mutants, S55A, S65A, and 
SIOOA，failed to undergo a mobility shift, indicating that ERK could potentially 
phosphorylate BiniEL at these three sites. In our study, active, phosphorylated forms of 
ERK were not detected in Sup-Tl cells (Fig. 3.21). Furthermore, two specific MEK 
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inhibitors, PD98059 and U0126, failed to block degradation of BiniEL (Fig. 3.22). 
Therefore, the ERK pathway is not likely to be responsible for phosphorylation of BiniEL 
in the Sup-Tl model. 
Likewise, a very recent study in an IL-3-dependent B-cell line demonstrated that Akt, 
a prosurvival kinase, is also capable to phosphorylate BiniEL (Qi et al, 2006). The 
IL-3-induced appearance of multiple, phosphorylated species of BiniEL was partially 
blocked by the PI3-K inhibitor, LY294002. In vitro kinase assays showed that 
recombinant Akt could directly phosphorylate a GST-BiniEL fusion protein (Qi et al,, 
2006). However, our data suggest that Akt pathway is not responsible for the 
phosphorylation of BiniEL in Sup-Tl cells. Although Akt is constitutively active (Fig. 
3.21), addition of the PI3-K inhibitors, LY294002 and wortmannin, could not restore the 
BimEL level (Fig. 3.22). 
In fact, we showed that the JNK pathway is necessary to promote BiniEL 
phosphorylation and its turnover. Blockage of the JNK pathway by a specific inhibitor, 
SP600125, yielded elevated level of BiniEL in the Sup-Tl cells (Fig. 3.22), suggesting that 
proteosomal degradation of BiniEL requires, at least in part, an activated JNK pathway. 
Furthermore, BiniEL species with higher molecular masses were no longer detected in the 
SP600125-treated cells (Fig. 3.22 and 3.23). Thus, phosphorylation of BimEL seems to be 
exclusively depended on the JNK pathway. JNK phosphorylation of Bim has been 
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demonstrated in fibroblasts (Lei and Davis, 2003) and neurons (Putcha et al., 2003). In 
fibroblasts, JNK phosphorylation of Bimt causes its release from the dynein motor 
complex, thereby allowing it to induce Bax-dependent apoptosis. In neurons, the 
mechanism by which JNK phosphorylation affects the pro-apoptotic activity of BiniEL is 
still unclear. Nevertheless, evidence of Bim phosphorylation by JNK that has been 
documented so far is linked to the potentiation of apoptosis. Here we show for the first 
time that BimEL phosphorylation by the JNK pathway could plays an anti-apoptotic role 
by targeting BiniEL for degradation via the proteosome. The different biological 
consequences of JNK phosphorylation of BimEL may have resulted from analysis of 
different types of tissues, perhaps indicating cell-type specific regulation of Bim. Of note, 
despite no known kinase downstream of JNK has been identified, it is not yet clear 
whether JNK itself is the kinase responsible for phosphorylating BiniEL- Further studies 
should be directed to define the identity of the kinase and the sites of phosphorylation. 
Numerous evidence shows that JNK functions as a pro-apoptotic kinase (Davis, 
2003). However, a recent study revealed that JNK can also suppress apoptosis by 
phosphorylating the pro-apoptotic Bcl-2 family protein, Bad (Yu et al., 2004). Thus, JNK 
can also function as an anti-apoptotic kinase. In this study, we demonstrate that the JNK 
axis can also suppress apoptosis in T-ALL Sup-Tl cells by phosphorylation of BimEL. 
In conclusion, we have identified a novel mechanism of chemoresistance in T-ALL 
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cells (Fig. 4.1). Our findings also provide new insights into how the JNK pathway 
regulates BiniEL level in leukemic cells. It will be of interest to determine in future studies 
whether the cellular Bim level is also associated with resistance to antileukemic agents in 
T-ALL patients. It is expected the findings of this study will help to develop novel, 
target-based strategies for the treatment of resistant T-ALL. 
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Fig. 4.1 The apoptosis resistance mechanisms in Sup-Tl cells. 
Constitutively active JNK phosphorylates the newly synthesized BiniEL 
in Sup-Tl cells. Phosphorylated BiniEL is then targeted to the 
proteosome in which ubiquitination may be involved in this process. 
The proteosome then degrades BiniEL so that its protein level is 
significantly reduced. The reduced BimEL level is not sufficient to 
inhibit the anti-apoptotic functions of the pro-survival Bcl-2 family 
proteins. Consequently, the release of mitochondrial cytochrome c, 
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